資料簡介
Recombinant human Viperin
endoplasmic reticulum-associated; interferon-inducible; cig 33; CIG 5; cig-33; CIG-5; CIG33; CIG5; Cytomegalovirus induced gene 5 protein; Cytomegalovirus-induced gene 5 protein; Radical S-adenosyl methionine domain-containing protein 2; RSAD 2; Rsad2; RSAD2_HUMAN; RSDA-2; VIG 1; vig1; Viperin; Virus inhibitory protein; virus inhibitory protein endoplasmic reticulum associated interferon inducible.
濃度:1mg/ ml
來源:Recombinant Human
純度:≥95% SDS-PAGE
表達(dá)系統(tǒng):Escherichia coli
標(biāo)簽:His tag
蛋白長度:Full length protein
內(nèi)毒素水平:<1.000 Eu/µg
純化方法:HPLC
應(yīng)用:SDS-PAGE,Western blot,ELISA
Biological activity,immunology research
保存:-20℃
保質(zhì)期:1年
Viperin is a 361 amino acid protein that is involved in antiviral defense against pathogens such as Hep C, Cytomegalovirus and HIV-1. Localized to the cytosolic side of the endoplasmic reticulum and relocated to the Golgi apparatus upon viral infection, RSAD2 is thought to prevent viral budding by disrupting lipid rafts at the plasma membrane and supporting the Interferon-induced antiviral state of the cell. Additionally, RSAD2 can bind to and inactivate FDPS (an enzyme that is crucial for the synthesis of cholesterol and geranylated and farnesylated proteins), thereby playing a role in lipid synthesis. Overexpression of RSAD2 leads to abnormal lipid accumulation that is associated with atherosclerosis, a chronic inflammatory disease characterized by hardened arteries.
產(chǎn)品名稱:Rabbit Anti-Viperin antibody
Rabbit Anti-Viperin
別名:endoplasmic reticulum-associated; interferon-inducible; cig 33; CIG 5; cig-33; CIG-5; CIG33; CIG5; Cytomegalovirus induced gene 5 protein; Cytomegalovirus-induced gene 5 protein; Radical S-adenosyl methionine domain-containing protein 2; RSAD 2; Rsad2; RSAD2_HUMAN; RSDA-2; VIG 1; vig1; Viperin; Virus inhibitory protein; virus inhibitory protein endoplasmic reticulum associated interferon inducible.
來源:Rabbit
克隆類型:Polyclonal
濃度:1mg/ml
亞型:IgG
應(yīng)用: WB=1:1000-1:2000,Elisa=1:1000-1:2000,IHC-P=1:100-500,IHC-F=1:100-500,ICC/IF=1:100-500,IF=1:100-500
反應(yīng):(predicted: Human,Mouse,Rat,Rabbit,Pig,Sheep,Cow,Chicken,Dog,Horse)
理論分子量:42kDa
免疫原:KLH conjugated synthetic peptide derived from human Viperin
保存:-20℃
保質(zhì)期:1年
單克隆抗體
產(chǎn)品名稱:Anti-Viperin antibody
Mouse Anti-Viperin
別名:endoplasmic reticulum-associated; interferon-inducible; cig 33; CIG 5; cig-33; CIG-5; CIG33; CIG5; Cytomegalovirus induced gene 5 protein; Cytomegalovirus-induced gene 5 protein; Radical S-adenosyl methionine domain-containing protein 2; RSAD 2; Rsad2; RSAD2_HUMAN; RSDA-2; VIG 1; vig1; Viperin; Virus inhibitory protein; virus inhibitory protein endoplasmic reticulum associated interferon inducible.
來源:Mouse
克隆類型:Monoclonal
濃度:1mg/ml
亞型:IgG
應(yīng)用: WB=1:1000-1:2000,Elisa=1:1000-1:2000,IHC-P=1:100-500,IHC-F=1:100-500,ICC/IF=1:100-500,IF=1:100-500
反應(yīng): Human
理論分子量:42kDa
免疫原:KLH conjugated synthetic peptide derived from human Viperin
保存:-20℃
保質(zhì)期:1年
Viperin is a 361 amino acid protein that is involved in antiviral defense against pathogens such as Hep C, Cytomegalovirus and HIV-1. Localized to the cytosolic side of the endoplasmic reticulum and relocated to the Golgi apparatus upon viral infection, RSAD2 is thought to prevent viral budding by disrupting lipid rafts at the plasma membrane and supporting the Interferon-induced antiviral state of the cell. Additionally, RSAD2 can bind to and inactivate FDPS (an enzyme that is crucial for the synthesis of cholesterol and geranylated and farnesylated proteins), thereby playing a role in lipid synthesis. Overexpression of RSAD2 leads to abnormal lipid accumulation that is associated with atherosclerosis, a chronic inflammatory disease characterized by hardened arteries.
相關(guān)產(chǎn)品
免責(zé)聲明
- 凡本網(wǎng)注明“來源:化工儀器網(wǎng)”的所有作品,均為浙江興旺寶明通網(wǎng)絡(luò)有限公司-化工儀器網(wǎng)合法擁有版權(quán)或有權(quán)使用的作品,未經(jīng)本網(wǎng)授權(quán)不得轉(zhuǎn)載、摘編或利用其他方式使用上述作品。已經(jīng)本網(wǎng)授權(quán)使用作品的,應(yīng)在授權(quán)范圍內(nèi)使用,并注明“來源:化工儀器網(wǎng)”。違反上述聲明者,本網(wǎng)將追究其相關(guān)法律責(zé)任。
- 本網(wǎng)轉(zhuǎn)載并注明自其他來源(非化工儀器網(wǎng))的作品,目的在于傳遞更多信息,并不代表本網(wǎng)贊同其觀點和對其真實性負(fù)責(zé),不承擔(dān)此類作品侵權(quán)行為的直接責(zé)任及連帶責(zé)任。其他媒體、網(wǎng)站或個人從本網(wǎng)轉(zhuǎn)載時,必須保留本網(wǎng)注明的作品第一來源,并自負(fù)版權(quán)等法律責(zé)任。
- 如涉及作品內(nèi)容、版權(quán)等問題,請在作品發(fā)表之日起一周內(nèi)與本網(wǎng)聯(lián)系,否則視為放棄相關(guān)權(quán)利。